American Journal of Cardiovascular Drugs

, Volume 13, Issue 1, pp 1–4 | Cite as

A Vaccine against Streptococcus pyogenes

The Potential to Prevent Rheumatic Fever and Rheumatic Heart Disease
  • Luiza Guilherme
  • Frederico Moraes Ferreira
  • Karen Francine Köhler
  • Edilberto Postol
  • Jorge Kalil
Leading Article


Streptococcus pyogenes causes severe, invasive infections such as the sequelae associated with acute rheumatic fever, rheumatic heart disease, acute glomerulonephritis, uncomplicated pharyngitis, and pyoderma. Efforts to produce a vaccine against S. pyogenes began several decades ago, and different models have been proposed. We have developed a vaccine candidate peptide, StreptInCor, comprising 55 amino acid residues of the C-terminal portion of the M protein and encompassing both the T- and B-cell protective epitopes. The present article summarizes data from the previous 5 years during which we tested the immunogenicity and safety of StreptInCor in different animal models. We showed that StreptInCor overlapping peptides induced cellular and humoral immune responses of individuals bearing different HLA class II molecules. These results are consistent with peptides that have a universal vaccine epitope. The tridimensional molecular structure of StreptInCor was elucidated by nuclear magnetic resonance spectroscopy, which showed that its structure is composed of two microdomains linked by an 18-residue α-helix. Additionally, we comprehensively evaluated the structural stability of the StreptInCor peptide in different physicochemical conditions using circular dichroism. Additional experiments were performed with inbred, outbred, and HLA class II transgenic mice. Analysis of several organs of these mice showed neither deleterious nor autoimmune reactions even after a long period of vaccination, indicating that the StreptInCor candidate peptide could be considered as an immunogenic and safe vaccine.



This work was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), Brazil.


  1. 1.
    Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005;5(11):685–94.PubMedCrossRefGoogle Scholar
  2. 2.
    Barbosa PJB, Müller RE, Latado AL, Achutti AC, Ramos AIO, Weksler C, et al. (2009) Diretrizes Brasileiras para Diagnóstico, Tratamento e Prevenção da Febre Reumática da Sociedade Brasileira de Cardiologia, da Sociedade Brasileira de Pediatria e da Sociedade Brasileira de Reumatologia (Brazilian guidelines for the diagnosis, treatment and prevention of rheumatic fever). Arq Bras Cardiol. 93(3 Suppl 4):1–18.Google Scholar
  3. 3.
    Fischetti VA, Windels M. Mapping the immunodeterminants of the complete streptococcal M6 protein molecule. Identification of an immunodominant region. J Immunol. 1988;141(10):3592–9.PubMedGoogle Scholar
  4. 4.
    Olive C, Clair T, Yarwood P, Good MF. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope. Vaccine. 2002;20(21–22):2816–25.PubMedCrossRefGoogle Scholar
  5. 5.
    Kotloff KL, Corretti M, Palmer K, Campbell JD, Reddish MA, Hu MC, Wasserman SS, Dale JB. Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial. JAMA. 2004;292(6):709–15.PubMedCrossRefGoogle Scholar
  6. 6.
    Robinson JH, Atherton MC, Goodacre JA, Pinkney M, Weightman H, Kehoe MA. Mapping T-cell epitopes in group A streptococcal type 5 M protein. Infect Immun. 1991;59(12):4324–31.PubMedGoogle Scholar
  7. 7.
    Batzloff M, Yan H, Davies M, Hartas J, Good M. Preclinical evaluation of a vaccine based on conserved region of M protein that prevents group A streptococcal infection. Indian J Med Res. 2004;119(Suppl):104–7.PubMedGoogle Scholar
  8. 8.
    McNeil SA, Halperin SA, Langley JM, Smith B, Warren A, Sharratt GP, Baxendale DM, Reddish MA, Hu MC, Stroop SD, Linden J, Fries LF, Vink PE, Dale JB. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin Infect Dis. 2005;41(8):1114–22.PubMedCrossRefGoogle Scholar
  9. 9.
    Guilherme L, Faé KC, Higa F, Chaves L, Oshiro SE, Freschi de Barros S, Puschel C, Juliano MA, Tanaka AC, Spina G, Kalil J. Towards a vaccine against rheumatic fever. Clin Dev Immunol. 2006;13(2–4):125–32.PubMedCrossRefGoogle Scholar
  10. 10.
    Guilherme L, Postol E, Freschi de Barros S, Higa F, Alencar R, Lastre M, Zayas C, Puschel CR, Silva WR, Sa-Rocha LC, Sa-Rocha VM, Pérez O, Kalil J. A vaccine against S. pyogenes: design and experimental immune response. Methods. 2009;49(4):316–21.PubMedCrossRefGoogle Scholar
  11. 11.
    Pandey M, Batzloff MR, Good MF. Mechanism of protection induced by group A Streptococcus vaccine candidate J8-DT: contribution of B and T-cells towards protection. PLoS One. 2009;4(4):e5147.PubMedCrossRefGoogle Scholar
  12. 12.
    Steer AC, Batzloff MR, Mulholland K, Carapetis JR. Group A streptococcal vaccines: facts versus fantasy. Curr Opin Infect Dis. 2009;22(6):544–52.PubMedCrossRefGoogle Scholar
  13. 13.
    Guilherme L, Alba MP, Ferreira FM, Oshiro SE, Higa F, Patarroyo ME, Kalil J. Anti-group A streptococcal vaccine epitope: structure, stability, and its ability to interact with HLA class II molecules. J Biol Chem. 2011;286(9):6989–98.PubMedCrossRefGoogle Scholar
  14. 14.
    Brandau DT, Jones LS, Wiethoff CM, Rexroad J, Middaugh CR. Thermal stability of vaccines. J Pharm Sci. 2003;92(2):218–31.PubMedCrossRefGoogle Scholar
  15. 15.
    Acevedo R, Callicó A, del Campo J, González E, Cedré B, González L, Romeu B, Zayas C, Lastre M, Fernández S, Oliva R, García L, Pérez JL, Pérez O. Intranasal administration of proteoliposome-derived cochleates from Vibrio cholerae O1 induce mucosal and systemic immune responses in mice. Methods. 2009;49:309–15.PubMedCrossRefGoogle Scholar
  16. 16.
    Guerino MT, Postol E, Demarchi LM, Martins CO, Mundel LR, Kalil J, Guilherme L. HLA class II transgenic mice develop a safe and long lasting immune response against StreptInCor, an anti-group A streptococcus vaccine candidate. Vaccine. 2011;29(46):8250–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Luiza Guilherme
    • 1
    • 2
    • 4
  • Frederico Moraes Ferreira
    • 1
    • 2
  • Karen Francine Köhler
    • 1
    • 2
  • Edilberto Postol
    • 1
    • 2
  • Jorge Kalil
    • 1
    • 2
    • 3
  1. 1.Heart Institute (InCor), Laboratory of ImmunologyUniversity of São PauloSão PauloBrazil
  2. 2.Institute for Investigation in ImmunologyNational Institute for Science and TechnologySão PauloBrazil
  3. 3.Clinical Immunology and Allergy Division, Department of Clinical Medicine, School of MedicineUniversity of São PauloSão PauloBrazil
  4. 4.Laboratório de ImunologiaInstituto do Coração (HC-FMUSP)São PauloBrazil

Personalised recommendations